XT
LXEO icon

XTX Topco’s Lexeo Therapeutics LXEO Stock Holding History

XTX Topco’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$678K Buy
145,556
+44,949
+45% +$243K 0.01% 2152
2026
Q1 		$577K Buy
100,607
+89,463
+803% +$634K 0.01% 1905
2025
Q4 		$111K Sell
11,144
-15,571
-58% -$142K ﹤0.01% 2608
2025
Q3 		$177K Buy
+26,715
New +$129K 0.01% 1887

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

XTX Topco's LXEO Position: Q2 2026 in Review

XTX Topco increased its Lexeo Therapeutics (LXEO) stake by 45% in Q2 2026, buying an estimated $243K and bringing the position to 145,556 shares worth $678K. The position accounts for 0.01% of the portfolio, ranked #2152.

XTX Topco first reported a position in LXEO in Q3 2025 and has held it in 4 quarters since. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • XTX Topco held 145,556 shares of Lexeo Therapeutics worth $678K as of Q2 2026.
  • XTX Topco bought 44,949 Lexeo Therapeutics shares in Q2 2026, an estimated $243K.
  • Lexeo Therapeutics made up 0.01% of XTX Topco's portfolio in Q2 2026, its #2152 holding.
  • XTX Topco first reported a position in Lexeo Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.